New York, USA, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Neuroblastoma Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 25+ Companies Working in the Domain
DelveInsight’s neuroblastoma pipeline report depicts a robust space with 25+ active players working to develop 20+ pipeline therapies for neuroblastoma treatment.
DelveInsight’s 'Neuroblastoma Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline neuroblastoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the neuroblastoma pipeline domain.
Key Takeaways from the Neuroblastoma Pipeline Report
- DelveInsight’s neuroblastoma pipeline report depicts a robust space with 25+ active players working to develop 20+ pipeline therapies for neuroblastoma treatment.
- Key neuroblastoma companies such as Clarity Pharmaceuticals Ltd, Eli Lilly and Company, Laboratorio Elea Phoenix S.A., PersonGen BioTherapeutics (Suzhou) Co., Ltd., Advanced Accelerator Applications, K C Pharmaceuticals Inc., Curis, Inc., Pfizer, Valent Technologies, LLC, UGISense AG, Y-mAbs Therapeutics, Ascentage Pharma, Kuur Therapeutics, Cell Medica, Autolus, NanoPharmaceuticals, Aptorum Group, and others are evaluating new drugs for neuroblastoma to improve the treatment landscape.
- Promising neuroblastoma pipeline therapies in various stages of development include 67Cu-SARTATE, LY3295668, Racotumomab, TAA06, Iobenguane I-131, 177Lu-DOTATATE, Eflornithine, CUDC-907, Lorlatinib, VAL-413, Ugimers, Omburtamab, Alrizomadlin, KUR-501, Nivatrotamab, CMD-501, DFMO, AUTO6, BG-P-TAT, SACT 1, and others.
- In July 2022, PersonGen Biotherapeutics announced that the Center for Drug Evaluation (CDE) of NMPA had cleared the company’s Investigational New Drug (IND) application for TAA06, an engineered autologous cell therapy targeting B7-H3 for the treatment of R/R Neuroblastoma.
- In February 2022, Clarity Pharmaceuticals announced that it had completed cohort 1 and advanced to cohort 2 in the 64Cu/67Cu SARTATE™ Neuroblastoma trial (CL04 trial).
- In March 2022, Ascentage Pharma announced that its novel MDM2-p53 inhibitor, alrizomadlin (APG-115), was granted a Rare Pediatric Disease (RPD) designation by the US Food and Drug Administration (FDA) for the treatment of neuroblastoma.
- In May 2022, Aptorum Group Limited announced the finalized data from the Phase 1 clinical trial of SACT-1, a repurposed small molecule drug targeting Neuroblastoma and potentially other cancer types. The study treatments were well tolerated, and no subjects were discontinued from study participation because of adverse events. No serious adverse events were reported during the study. The phase 1 clinical data also suggested that any QT interval after oral administration of SACT-1 at 150mg was well within clinically acceptable limits.
- In January 2021, Kuur Therapeutics announced clinical updates for both the phase 1 GINAKIT2 study of KUR-501 (autologous GD2 CAR-NKT cells) being tested in patients with relapsed/refractory (R/R) neuroblastoma and the phase 1 ANCHOR study of KUR-502 (off-the-shelf CD19 CAR-NKT cells) being evaluated in patients with R/R CD19 positive malignancies. Complete responses and evidence of tumor homing have been observed in both trials, and the CAR-NKT cell therapy has been safe and well-tolerated.
Request a sample and discover the recent advances in neuroblastoma treatment drugs @Neuroblastoma Pipeline Report
The neuroblastoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage neuroblastoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the neuroblastoma clinical trial landscape.
Neuroblastoma Overview
Neuroblastoma is a deadly infant tumor. It can, however, happen to children under the age of five. Neuroblastoma is made up of neuroblasts that form in the medulla of an adrenal gland. However, the tumor may develop in the nerve tissue of the spinal cord, chest, or neck nerve tissue. A genetic mutation is responsible for neuroblastoma causes.
The most common neuroblastoma symptoms are abdominal pain, discomfort, and a feeling of fullness caused by an abdominal mass. Although neuroblastoma may be discovered as a mass on abdominal radiographs or the US, CT or MRI are used to confirm the neuroblastoma diagnosis and define the exact extent of the disease.
Neuroblastoma is the most common solid tumor in children, with a wide range of symptoms and neuroblastoma treatment responses. One of its characteristics is the generation of oxidative stress due to the buildup of reactive species required for cancer metabolism, proliferation, and progression.
Find out more about neuroblastoma treatment drugs @Drugs for Neuroblastoma Treatment
A snapshot of the Neuroblastoma Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| Racotumomab | Recombio | Phase II | Antibody-dependent cell cytotoxicity | Intradermal |
| 67Cu MeCOSar Octreotate | Clarity Pharmaceuticals | Phase I/II | Ionising radiation emitter | Intravenous |
| LY3295668 | Eli Lilly and Company | Phase I | Aurora kinase A inhibitor | Oral |
| SACT 1 | Aptorum Group | Phase I | Proto-oncogene protein c-myc translation inhibitor | Oral |
| TAA06 | PersonGen BioTherapeutics | Phase I | T lymphocyte replacement | Parenteral |
Learn more about the emerging neuroblastoma pipeline therapies @Neuroblastoma Clinical Trials
Neuroblastoma Therapeutics Assessment
The neuroblastoma pipeline report proffers an integral view of neuroblastoma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Neuroblastoma Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Infusion, Intradermal, Intramuscular, Intranasal, Intravaginal, Oral, Parenteral, Subcutaneous, Topical
- Therapeutics Assessment By Molecule Type: Vaccines, Monoclonal antibody, Peptides, Polymer, Small molecule
- Therapeutics Assessment By Mechanism of Action: Ionising radiation emitters, Ornithine decarboxylase inhibitors, Retinoic acid receptor agonists, Aurora kinase A inhibitors, Cell division inhibitors, Antibody-dependent cell cytotoxicity, Immunostimulants, Cell death stimulants, Proto-oncogene protein c-myc translation inhibitors, Glycogen synthase kinase 3 beta inhibitors
- Key Neuroblastoma Companies: Clarity Pharmaceuticals Ltd, Eli Lilly and Company, Laboratorio Elea Phoenix S.A., PersonGen BioTherapeutics (Suzhou) Co., Ltd., Advanced Accelerator Applications, K C Pharmaceuticals Inc., Curis, Inc., Pfizer, Valent Technologies, LLC, UGISense AG, Y-mAbs Therapeutics, Ascentage Pharma, Kuur Therapeutics, Cell Medica, Autolus, NanoPharmaceuticals, Aptorum Group, and others.
- Key Neuroblastoma Pipeline Therapies: 67Cu-SARTATE, LY3295668, Racotumomab, TAA06, Iobenguane I-131, 177Lu-DOTATATE, Eflornithine, CUDC-907, Lorlatinib, VAL-413, Ugimers, Omburtamab, Alrizomadlin, KUR-501, Nivatrotamab, CMD-501, DFMO, AUTO6, BG-P-TAT, SACT 1, and others.
Dive deep into rich insights for new drugs for neuroblastoma treatment, visit @Neuroblastoma Drugs
Table of Contents
| 1. | Neuroblastoma Pipeline Report Introduction |
| 2. | Neuroblastoma Pipeline Report Executive Summary |
| 3. | Neuroblastoma Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Neuroblastoma Clinical Trial Therapeutics |
| 6. | Neuroblastoma Pipeline: Late Stage Products (Pre-registration) |
| 7. | Neuroblastoma Pipeline: Late Stage Products (Phase III) |
| 8. | Neuroblastoma Pipeline: Mid Stage Products (Phase II) |
| 9. | Neuroblastoma Pipeline: Early Stage Products (Phase I) |
| 10. | Neuroblastoma Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Neuroblastoma Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Neuroblastoma Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the neuroblastoma pipeline therapeutics, reach out @Neuroblastoma Treatment Drugs
Related Reports
Neuroblastoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key neuroblastoma companies including Illumina Radiopharmaceuticals, Recombio, United Therapeutics, Molecular Insight Pharmaceuticals, among others.
Neuroblastoma Epidemiology Forecast
Neuroblastoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted neuroblastoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Pediatric Neuroblastoma Pipeline
Pediatric Neuroblastoma Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pediatric neuroblastoma companies, including GE Healthcare, Millennium Pharmaceuticals, Genentech, Actuate Therapeutics, among others.
Pediatric Neuroblastoma Market
Pediatric Neuroblastoma Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pediatric neuroblastoma companies including GE Healthcare, Millennium Pharmaceuticals, Genentech, Actuate Therapeutics, among others.
Pediatric Neuroblastoma Epidemiology
Pediatric Neuroblastoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted pediatric neuroblastoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | Chimeric Antigen Receptor (CAR) T-Cell Therapy Market | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Report | Crows Feet Market | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market | Insulin Glargine Biosimilar Insight
Related Healthcare Services
Healthcare Business Consulting
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
